This belief is grounded in its demonstrated efficacy in conditions of a comparable nature, such as fibromyalgia and CFS, by influencing processes that impact the immune system, such as reducing levels of C-reactive protein and brain-derived neurotrophic factor, which are considered a key element in a variety of neuroplasticity processes such as pain modulation, nociception, and hyperalgesia [9, 13, 22, 68]. This evidence concerns the gene BDNF and myalgic encephalomeyelitis/chronic fatigue syndrome.